*
*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice
54321
Implement targeted therapies for acute myeloid leukemia.
Implement targeted therapies for multiple myeloma.
Assess your ability to review the role and timing of intestinal microbiome in cancer immunotherapy.
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA=Not Applicable
54321NA
Next Steps in CAR T-Cell Therapies - Michel Sadelain, M.D., Ph.D.
Do We Need a CAR T-Cell Registry? - Marcelo Pasquini, M.D.
The Role of Intestinal Microbiome in Cancer Immunotherapy - Marcel van den Brink, M.D., Ph.D.
Developing Next Generation T-Cell Therapies for AML - Catherine Bollard, M.D.
Taking the Next Steps to Improving Outcomes in ALL - Wendy Stock, M.D.
The Role of Allogeneic Hematopoietic Stem Cell Transplantation for ALL in 2024 - Robert Soiffer, M.D.
Updates on Treatment Approaches in Diffuse Large B-Cell Lymphoma (DLBCL) - Matthew Matasar, M.D.
CAR T-Cell Therapies for NHL - Craig Sauter, M.D.
*
*
*
*
*
*
*
*